Step in as CEO or operating lead to get a program funded, staffed, and moving with a clean handoff when it's built.
Positioning, materials, and investor and partner strategy from seed through Series A and BD deals.
Stand up a lean, outsourced Chemistry, Manufacturing, and Controls (CMC) and clinical network. Real velocity without building fixed infrastructure.
A senior operator's read on strategy, milestones, and risk for boards and investors who want the ground truth.
The biotechnology industry has entered a new era where traditional strategies no longer guarantee success. The New Rules of Biotech: A Founder’s Guide to Building Great Companies introduces a practical approach for founders, executives, investors, and advisors who are building companies in today’s rapidly changing market. Unlike traditional business books,
The biotech industry has changed significantly over the last few years. Capital is more expensive, regulatory expectations have increased, and investors are placing greater emphasis on efficiency, measurable milestones, and long-term value creation. The New Rules of Biotech explains why founders must rethink the traditional company-building process. From selecting the
David Craig brings decades of experience in pharmaceutical and biotechnology company building to this practical guide. His insights are based on real-world challenges faced by founders navigating today’s competitive and constantly evolving biotech industry. The book covers every stage of company development, including scientific strategy, fundraising, clinical planning, business development,
